Shanghai Fosun Pharma’s FCN-159 Receives Priority Review for Pediatric Neurofibromatosis Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has achieved a significant milestone...
Asymchem Laboratories Enters European Market with Pfizer’s UK API Plant and R&D Lab Purchase
Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading China-based Contract Development and Manufacturing Organization...
China Invalidates Heart Failure Patent for Dapagliflozin, Maintains Protection for Kidney Disease Use
The China National Intellectual Property Administration (CNIPA) has announced a pivotal decision concerning the patent...
Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
GSK Confronted with Whistleblower Allegations Over Zantac and NDMA Link
GlaxoSmithKline (GSK; NYSE: GSK), the UK-based pharmaceutical giant, is facing legal action in the form...
Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...
Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI
Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US...
Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...
Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...
Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca
Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...
Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial
Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...
AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...
NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...
BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...
Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads
Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...
BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...
China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...
Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...